Marker Therapeutics terminates $25M equity purchase agreement with Lincoln Park Capital

Marker Therapeutics, Inc.

Terminated Purchase Agreement with Lincoln Park Capital Fund effective March 1, 2024.
Only 12,500 shares were sold under the agreement, generating ~$33,000 in proceeds.
Company projects financial runway through Q4 2025; no immediate capital need.
No early termination penalties; 1.8M commitment shares previously issued to LPC.

item 1.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Marker Therapeutics, Inc. terminated Purchase Agreement with Lincoln Park Capital Fund, LLC (effective 2024-03-01).

Action: termination
Agreement: equity purchase
Counterparty: Lincoln Park Capital Fund, LLC
Effective: 2024-03-01

Exact text from the filing

On February 29, 2024, Marker Therapeutics, Inc. (the “Company”) delivered notice to Lincoln Park Capital Fund, LLC, an Illinois limited liability company (“LPC”), terminating the Purchase Agreement, dated December 12, 2022 (the “Purchase Agreement”), with LPC effective March 1, 2024

View on SEC.gov

737 material agreements filed in the last 30 days. Browse all material agreements →

Marker Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-029638

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.